Introduction {#Sec1}
============

Anhedonia is defined as 'markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day' (Association and Association [@CR4]). Although anhedonia has long been considered a prominent symptom in neuropsychiatric disorders, especially major depressive disorder (MDD) and schizophrenia (SZ) (Association and Association [@CR4]), its underlying neurobiological mechanisms remain poorly understood. Recently, evidence has emerged to indicate overlap of behavioral, cognitive processing and neurobiological abnormalities between MDD and SZ patients with marked clinical anhedonia (Gradin et al. [@CR52]; Whitton et al. [@CR138]). As a result of this finding and the advocacy of the NIMH Research Domain Criteria (RDoC) project (Insel et al. [@CR63]), investigators are seeking to use the basic behavioral dimension of functioning, rather than traditional diagnostic categories, to identify transdiagnostic neural markers of anhedonia (Corral-Frias et al. [@CR19]; Cuthbert and Insel [@CR21]; Markou et al. [@CR84]). A quantitative meta-analysis of pooled neuroimaging studies of anhedonia in MDD and SZ, discussed within the RDoC framework, is a promising approach to investigate the neural substrates of anhedonia. However, it is important to be mindful of the complexity and multi-faceted nature of clinical anhedonia to understand neuroimaging studies in this field.

Based on the latest studies, anhedonia is a multidimensional construct and should not simply be considered as 'loss of an ability to experience pleasure'. Deficits in other reward processes, such as valuation, motivation and decision-making, may lead to behaviors that can be interpreted as anhedonia (Der-Avakian and Markou [@CR25]; Gold et al. [@CR48]; Leventhal et al. [@CR82]). Hence, distinguishing the deficits in different cognitive subcomponents of anhedonia is essential to identify its neurobiological substrates. Some investigators have suggested dichotomizing anhedonia into 'consummatory anhedonia' (the hedonic response to rewards) and 'anticipatory anhedonia' (diminished motivation to pursue rewards) (Treadway and Zald [@CR121]). Others hold that studies should move away from conceptualization of anhedonia as a steady-state, mood-like phenomena, and instead focus on the reward-related motivational/decisional-making aspect (Treadway et al. [@CR123]; Whitton et al. [@CR138]). Still others propose to bridge the gap between preclinical and clinical studies by isolating the neural substrates of various processes, such as sensing a pleasant stimulus or anticipating expected rewards, computing value and associated costs, determining effort required, deciding to obtain the reward, increasing motivation and performing the action (Der-Avakian and Markou [@CR25]). Changing research strategies and models demand more complicated and elaborate experimental designs to investigate the underlying neural bases of anhedonia.

Several experimental paradigms have been developed in last decade to explore the specific processes of anhedonia beyond hedonic capacity, such as anticipation, motivation and reinforcement learning. However, only a few task-based functional magnetic resonance imaging (fMRI) studies have separated anhedonia deficits into different processing stages. Early neuroimaging studies frequently adopted the passive picture-viewing task based on the viewpoint that anhedonia represents a diminished responsiveness to positive-valence stimuli (Hooker et al. [@CR62]; Mitterschiffthaler et al. [@CR88]; Shi et al. [@CR112]). More recently, some experimental reward paradigms, especially the monetary incentive delay task (MID) (Admon et al. [@CR2]; Balodis and Potenza [@CR5]; Elman et al. [@CR37]), have been increasingly used to detect neural substrates of anhedonia. Those studies have typically explored brain activity impairments in experience/consummatory and motivational/anticipatory stages separately, and they discussed the link between anhedonia and the reward-processing components of 'liking' and 'wanting' from the preclinical literature (Berridge and Robinson [@CR12]; Dillon et al. [@CR29]). Specifically, the consummatory stage was primarily associated with dysfunctions of reward coding and evaluation, and the anticipatory stage was associated with advanced cognitive functions, such as motivation and decision-making. Recently, although other paradigms have been developed to assess a specific aspect of anhedonia-related processing, such as the Effort Expenditure for Rewards Task (EEfRT), which focuses on motivation and effort-based decision-making (Fervaha et al. [@CR42]; Treadway et al. [@CR122]; Yang et al. [@CR139]) and the Probabilistic Learning Task (PRT), which focuses on reward learning (Pizzagalli et al. [@CR101]), no neuroimaging studies have used these two paradigms in MDD or SZ patients. In fact, to date the majority of studies have explored the neurobiology of the three subdomains of anhedonia, which involve different neurocognitive process and functional neuroanatomy bases: consummatory anhedonia, anticipatory anhedonia and emotional (positive stimuli) processing (Berridge and Robinson [@CR12]; Dillon et al. [@CR29]; Smoski et al. [@CR115]).

Neuroimaging studies of the three subdomains of anhedonia in MDD and SZ patients have reached inconsistent and even contradictory findings. For instance, several studies that used a reward-related task, most often MID, indicated ventral striatal blunting in depressed adults (Knutson et al. [@CR75]; Kumar et al. [@CR79]; Ubl et al. [@CR127]) and even in never-depressed youth with family history of MDD (Gotlib et al. [@CR51]). Another study using the same experimental paradigm (MID) showed no significant group difference in ventral striatum between unmedicated MDD and controls after correction (Pizzagalli et al. [@CR102]). Furthermore, Pizzagalli et al. ([@CR101]) reported decreased activation in dorsal anterior cingulate (dACC) during the MID task in MDD patients compared with healthy controls, whereas other studies found increased activation of dACC in MDD (Gorka et al. [@CR49]; Knutson et al. [@CR75]). Similar contradictory results have been observed in SZ patients, especially in the experience/consummatory stage. When presented with reward stimuli, SZ patients showed impairments in both ventral striatal and prefrontal areas (da Silva Alves et al. [@CR22]; Walter et al. [@CR133]), impairments in prefrontal cortex but not basal ganglia areas (Waltz et al. [@CR136]) or no impairments in either area (Mucci et al. [@CR90]; Simon et al. [@CR113]). These inconsistencies among studies may reflect differences in sample size, sample characteristics (average age, sexual ratio, medicated or not), paradigms used, and fMRI analysis methods.

The development of meta-analyses methods for neuroimaging data provide a valuable tool for combining data across diverse studies and building consensus in identification of neuroanatomical correlates of specific behavior. To date, the main methods used for the meta-analyses of neuroimaging data could be divided into two categories: the regions of interest (ROI) based meta-analytic methods, and the voxel-based meta-analytic methods. The ROI-based methods allow for optimal statistical analyses but are based on a priori hypotheses therefore being affected by a limited and potentially biased inclusion of brain regions (Rotge et al. [@CR108]; Radua and Mataix-Cols [@CR104]). On the other hand, voxel-based methods have a more exhaustive and unbiased inclusion of studies but have some statistically limitation. Activation likelihood estimation (ALE), proposed by Turkeltaub and Laird (Turkeltaub et al. [@CR125]; Laird et al. [@CR81]), is probably the most common algorithm for voxel-based meta-analyses.

Besides the clear mathematical logic and operation steps, ALE method has several advantages over ROI-based meta-analyses through inputting the foci of activation instead of labels, weighting the foci by the number of participants in each study, yielding a quantitative estimate of the probability of activation, identifying common activations across different studies (Laird et al. [@CR81]; Wager et al. [@CR131]; Eickhoff et al. [@CR34]; Eickhoff et al. [@CR35]). More importantly, the recent change from fixed-effects to random-effects inference in analyses (Eickhoff et al. [@CR34]) and the revision for multiple comparison correction (Eickhoff et al. [@CR35]) made ALE to become a more reliable statistic meta-analysis approach.

Therefore, the ALE meta-analysis method was used in this review to make an objective, systematic, and quantitative analysis of the previous literature and synthesize the anhedonia-related, task-based fMRI findings in MDD and SZ from three subdomains of anhedonia: consummatory anhedonia, anticipatory anhedonia, and emotional processing. Specifically, we first performed the within-group ALE meta-analyses to provide a context for interpreting the anhedonia-related between-group differences. In the between-group analysis, the transdiagnostic ALE analysis of the literature on MDD and SZ was examined to provide an integrated framework of the neural bases of anhedonia, and the analysis focused specifically on MDD or SZ was used later to dissociate specific anhedonia-related neurobiological impairments from potential disease general impairments. The transdiagnostic approach provides the opportunity to identify an overall neurobiological framework for a specific symptom or behavior across multiple disease states and has the potential to improve targeted treatment strategies.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Studies focused on the neurobiology of anhedonia in patients with MDD or SZ were identified through computerized literature searches using PubMed and Web of Science. We reviewed all papers published in the English language up to August 1, 2015. The key words used for the search were 'anhedonia', 'hedonic', 'emotional withdrawal', 'pleasure deficit', 'apathetical social withdrawal', 'functional magnetic resonance' and 'fMRI'. A total of 571 English publications were initially identified using this process. Another three articles were obtained from reference lists of prior reviews (Whitton et al. [@CR138]; Zhang et al. [@CR140]). In summary, these search procedures yielded an initial pool of 574 potential articles for inclusion.

In prior neuroimaging studies focused on anhedonia, the most common paradigms adopted were the MID, reinforcement learning task (RLT) and emotional experience task (EET). For MID, RLT or some modified reward tasks, subjects initially see a cue indicating that they will have an opportunity to obtain a certain amount of reward (e.g., money), then they perform a task, and they receive immediate feedback (by obtaining or not obtaining the reward). The process between the cue and the task refers to anticipation stage, and the in-the-moment experience during receipt of a reward refers to consummatory stage. Besides, the emotional experience task (EET) is associated with a passive viewing of positive-valence stimuli that requires no response. Therefore, based on different cognitive process, we divided anhedonia into three subdomains: anticipatory anhedonia, consummatory anhedonia, and emotional processing.

Inclusion criteria {#Sec4}
------------------

For the current meta-analysis, once duplicate articles were removed, the following eight inclusion criteria were utilized: (1) first-hand empirical studies; (2) subjects were healthy controls or patients with either MDD or SZ; (3) MDD or SZ were diagnosed according to DSM-IV(−TR) or ICD-10; (4) studies focused on anhedonia though task-related paradigms; (5) studies examined neuronal activity related to anhedonia using fMRI; (6) studies identified foci of task-related neural changes in active conditions (e.g., emotional picture or monetary gain) and/or contrasted an active and a control condition (neutral picture or fixation cross); (7) coordinates were reported in either standard Talairach space or Montreal Neurologic Institute (MNI) space. Figure [1](#Fig1){ref-type="fig"} shows the process of study identification and selection. From the identification and selection of studies, coordinate results of within-group activations and between-group differences were divided into 4 groups: activations in patients, activations in healthy controls, increases in patients relative to controls, and increases in controls relative to patients.Fig. 1Flowchart describing the process of study identification and selection

Activation likelihood estimation (ALE) procedure {#Sec5}
------------------------------------------------

Meta-analysis was performed using the ALE software implemented in GingerALE version 2.3.2 ([http://brainmap.org](http://brainmap.org/)). This ALE version used a random effect model and weighted for sample size of the original studies (Laird et al. [@CR81]). In ALE, activation foci reported in original studies are treated as 3D Gaussian distributions centered at the reported coordinates. Activation probabilities are then calculated for each standard-space voxel to construct ALE maps for contrasts of interest. To determine the reliability of the ALE map, null-distributions are generated by analyzing the distribution of ALE values across independent studies, which is conceptually similar to using permutation tests of individual voxels across experiments. The observed values in the ALE distribution are then compared to the null distribution in order to assign probability estimates to the observed (experimental) data.

For the present meta-analysis, single studies were used respectively to perform meta-analyses of anhedonia for each of the three subdomains. Coordinates of the foci of activation reported in MNI were transformed to Talairach space using the icbm2tal in GingerALE. The threshold of statistical significance was set at *p* \< 0.01 and corrected for multiple testing using the false discovery rate (FDR) with a minimum cluster size of 400 mm^3^. For visualization, whole-brain maps of thresholded ALE maps were imported into multi-image analysis GUI (MANGO; <http://ric.uthscsa.edu/mango>) and overlaid onto a standardized anatomical template in Talairach space ([www.brainmap.org/ale/colin1.1.nii](http://www.brainmap.org/ale/colin1.1.nii)).

Results {#Sec6}
=======

Article inclusion {#Sec7}
-----------------

Figure [1](#Fig1){ref-type="fig"} shows the study selection flowchart, and Table [1](#Tab1){ref-type="table"} shows the pooled data for all contrasts. A total of 32 articles with 684 healthy controls reporting 353 foci, and 28 articles with 562 patients reporting 214 foci were included in within-group analysis. A total of 57 articles (33 articles on MDD and 24 on SZ) with 986 patients and 1041 healthy controls and reporting 453 foci were included in the transdiagnostic meta-analysis. There were no significant differences in age or sex between patients (34.33 ± 8.55 years old; 51.09 % men) and healthy controls (32.12 ± 7.09 years old; 51.71 % men), MDD patients (36.40 ± 8.79 years old; 40.82 % men) and healthy controls (33.85 ± 8.42 years old; 39.80 % men) or between SZ patients (30.75 ± 6.96 years old; 63.64 % men) and healthy controls (31.85 ± 3.70 years old; 71.33 % men).Table 1Published fMRI studies included in the between-group ALE analysis of anhedonia across MDD and SZAuthor, yearContrastsHealthy controlsPatientsMedication (Y/N)ParadigmExperimental conditionStereotactic spaceAge (years)N (f/m)Age (years)N (f/m)Ubl et al. [@CR127]MDD vs. CON43.9628 (15/13)46.0030 (16/14)NMIDHigh reward vs. control conditionMNIGorka et al. [@CR49]CON, MDD vs. CON29.5018 (13/5)25.409 (6/3)Y(11.1 %)Reward anticipation taskReward vs. no incentiveMNIHall et al. [@CR58]MDD, CON, MDD vs. CON37.3829 (16/13)37.0229 (16/13)Y (100 %)RLTReward acquisitionTALFournier et al. [@CR44]MDD vs. CON32.6028 (16/12)30.6026 (18/8)Y (69.2 %)EETHappy facesTALStuhrmann et al. [@CR119]MDD, CON, MDD vs. CON40.3035 (21/14)40.1035 (21/14)Y (100 %)EETHappy vs. neutral facesMNIStoy et al. [@CR117]MDD, CON, MDD vs. CON39.5015 (5/10)41.9015 (5/10)NMIDGain vs. neutralTALRobinson et al. [@CR107]MDD vs. CON31.0014 (6/8)36.0013 (5/8)NRLTUnexpected rewardMNIDichter et al. [@CR28]MDD vs. CON27.9019 (12/7)24.5019 (15/4)Y (26.3 %)MIDReward vs. no-rewardMNIChantiluke et al. [@CR15]MDD vs. CON16.3021 (11/10)16.2020 (10/10)NRLTRewarded vs. non-rewarded targetTALDerntl et al. [@CR26]MDD vs. CON32.9015 (9/6)34.1015 (9/6)Y (86.7 %)EETHappy conditionMNISmoski et al. [@CR115]MDD vs. CON26.201334.409Y (44.4 %)MIDReward (or positive) vs. neutral coditionMNIGradin et al. [@CR52]MDD, SZ, CON, MDD vs. CON, SZ vs. CON40.6417 (7/10)45.2715 (6/9)Y (100 %)RLTUs(water) vs. csMNIBermpohl et al. [@CR9]CON, MDD vs. CON24.1021 (10/11)43.4015 (12/3)Y (93.3 %)EETCued vs. uncued emotional pictures; Emotional \> neutral expectancyMNIWalter et al. [@CR134]MDD vs. CON34.6024 (18/6)40.0019 (11/8)NEETEmotional pictures vs. at restMNIRemijnse et al. [@CR105]MDD vs. CON32.0027 (19/ 8)34.0020 (8/12)NRLTReward outcome vs. baselineMNIMcCabe et al. [@CR86]MDD vs. CON28.5014 (9/5)27.8013 (11/3)NEETPleasant stimulatesMNIPizzagalli et al. [@CR102]MDD vs. CON38.8031 (13/18)43.1730 (15/15)NMIDReward vs. no-rewardMNISmoski et al. [@CR114]MDD vs. CON30.8015 (9/6)34.8016 (9/7)NWOFReward vs. no-rewardTALOsuch et al. [@CR97]MDD vs. CON23.5015 (11/4)22.6016 (11/5)Y (18.6 %)EETFavorite vs. neutral musicTALForbes et al. [@CR43]MDD, CON, MDD vs. CON13.1028 (21/7)13.5015 (10/5)NRLTReward vs. no-rewardTALKnutson et al. [@CR75]MDD, CON, MDD vs. CON28.6712 (4/8)30.7114 (5/9)Y (100 %)MIDReward vs. no-rewardTALKumar et al. [@CR79]MDD, CON, MDD vs. CON42.0018 (11/7)45.3015 (9/6)Y (100 %)RLTUS(water) vs. CSMNISteele et al. [@CR116]MDD, CON, MDD vs. CON43.0014 (7/7)45.9015 (11/4)Y (93.3 %)Gambling taskWin feedbackMNIFu et al. [@CR46]MDD vs. CON42.8019 (11/8)43.2019 (13/6)NEETHappy facesTALEpstein et al. [@CR38]MDD, CON, MDD vs. CON32.0012 (7/5)35.6010 (9/1)NEETPositive wordsTALKeedwell et al. [@CR71]MDD, CON, MDD vs. CON36.0012 (8/4)43.0012 (8/4)Y (91.7 %)EETHappy vs. neutral stimuliTALGotlib et al. [@CR50]MDD vs. CON30.8018 (13/5)35.2018 (13/5)Y (50.0 %)EETHappy vs. neutral facesTALTremblay et al. [@CR124]MDD vs. CON29.3312 (7/5)34.8312(6/6)Y (100 %)EETOn condition vs. off conditionTALSurguladze et al. [@CR120]MDD vs. CON35.1014 (6/8)42.3016 (6/10)Y (56.3 %)EETHappy facial expressionsTALCanli et al. [@CR14]MDD vs. CON30.7015 (12/3)35.1015 (12/3)Y (46.7 %)EETHappy vs. neutral wordsTALMitterschiffthaler et al. [@CR88]MDD, CON, MDD vs. CON48.307 (7/0)46.307 (7/0)Y (100 %)EETPositive valence picturesTALKumari et al. [@CR80]MDD, CON, MDD vs. CON44.006 (6/0)47.006 (6/0)Y (100 %)Picture-caption pairs taskPositive P-C vs. Reference P-CTALJohnston et al. [@CR68]MDD, CON, MDD vs. CON50.7921(15/6)46.1419(15/4)Y (100 %)Pessiglione taskWin trailsMNIMucci et al. [@CR90]SZ, CON, SZ vs. CON31.9122 (12/10)33.1028 (10/18)Y (100 %)MIDReward vs. neutralTALChoi et al. [@CR16]SZ vs. CON29.1017 (7/10)29.1015 (5/10)Y (100 %)EETHedonic vs. neutral conditionTALda Silva Alves et al. [@CR22]SZ vs. CON34.5512(0/12)22.7010 (0/12)NMIDReward vs. no outcomeTALEsslinger et al. [@CR39]SZ vs. CON27.1027 (7/20)27.8027 (20/7)NReward taskReward vs. control conditionMNINielsen et al. [@CR94]SZ vs. CON29.7031 (9/22)25.9031 (9/22)NMIDGain vs. no-gainTALGrimm et al. [@CR54]SZ vs. CON28.9023 (17/6)30.3023 (17/6)Y (100 %)Reward taskFood vs. control stimuliMNIMorris et al. [@CR89]SZ, CON, SZ vs. CON32.9016 (8/8)13.0021 (7/14)Y (100 %)Reward-related taskUnexpected rewardMNIDowd and Barch [@CR31]SZ vs. CON33.2020 (6/14)31.4425 (7/18)Y (100 %)Reward prediction taskMoney vs. no-moneyTALUrsu et al. [@CR128]SZ, CON, SZ vs. CON28.7020 (7/13)28.8020 (5/15)Y (73.91 %)EETPleasant stimuliTALHarvey et al. [@CR60]SZ, CON, SZ vs. CON30.7026 (13/13)30.4030 (11/19)Y (80 %)EETPositive pictures vs. neutral picturesTALKoch et al. [@CR76]SZ, CON, SZ vs. CON29.7020 (8/12)35.2019 (7/12)Y (94.7 %)RLTPositive PETALDowd and Barch [@CR30]SZ, CON, SZ vs. CON36.2532 (11/21)36.8040 (14/26)Y (100 %)EETPositive vs. neutralTALSimon et al. [@CR113]SZ vs. CON25.2015 (5/10)26.3015 (5/10)Y (100 %)MIDReward vs. no rewardMNIWaltz et al. [@CR136]SZ vs. CON37.8017 (4/13)37.8017 (5/12)Y (100 %)MIDGain vs. lossMNIWaltz et al. [@CR135]SZ vs. CON37.1018 (4/14)37.7018 (5/13)Y (100 %)Pavlovian conditioning taskPositive TDE vs. negative TDETALWalter et al. [@CR133]SZ, CON, SZ vs. CON33.0016 (9/7)38.0016 (8/8)Y (100 %)MIDRewardMNIReske et al. [@CR106]SZ vs. CON35.301037.4010 (4/6)NEETHappinessMNISchlagenhauf et al. [@CR111]SZ, CON, SZ vs. CON30.1015 (3/12)30.1015 (3/12)NMIDGain vs. no outcomeMNIMurray et al. [@CR92]SZ, CON, SZ vs. CON26.0012 (3/9)26.0013 (4/9)Y (61.54 %)RLTReward prediction error vs. neutral prediction errorMNIJensen et al. [@CR67]SZ vs. CON36.5013 (4/9)37.6013 (3/10)Y (100 %)RLTCS +/ CS-MNISchlagenhauf et al. [@CR110]SZ, CON, SZ vs. CON31.8010 (1/9)30.5010 (1/9)Y (100 %)MIDGain vs. no moneyMNIJuckel et al. [@CR69]SZ, CON, SZ vs. CON30.6010 (8/2)31.5010 (8/2)Y (100 %)MIDGain vs. no outcomeTALJuckel et al. [@CR70]SZ, CON, SZ vs. CON31.7010 (0/10)26.8010 (0/10)NMIDGain vs. no outcomeTAL*MID* = Monetary Incentive Delay Task; *EET* = Emotional Experience/regulation Task; *RLT* = Reward Learning Task; *WOF* = Wheel of Fortune task; *MNI* = Montreal Neurological Institute coordinates; *TAL* = Talairach and Tournoux coordinates

Within-group ALE analysis {#Sec8}
-------------------------

### Healthy controls {#Sec9}

For reward consummatory (16 studies and 160 foci), ALE revealed a set of subcortical areas, including bilateral globus pallidus (GPe), bilateral red nucleus, right caudate body, left substania nigra (SN) and right putamen, left parahippocampal gyrus, as well as left medial frontal gyrus (mPFC). For reward anticipation (17 studies and 99 foci), ALE results showed robust activation of a broad cortical-subcortical network, including left GPe, right caudate head, left caudate body, bilateral red nucleus, right inferior frontal cortex (IFG), right superior temporal gyrus (STG), right insula, left mPFC and some midbrain areas, such as mammillary body. For the emotional processing (9 studies and 94 foci), several regions in frontal gyrus were activated to a greater degree, such as mPFC, MFG and IFG, as well as the middle temporal gyrus and fusiform gyrus (*p* \< 0.01, FDR corrected, cluster size \> 400 mm3, Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Table 2Within-group ALE meta-analysis results in healthy controls and patients (mixed MDD and SZ)ClusterAnatomical regionBAXYZVolume mm^3^Maximum ALE Value (10^−3^)Healthy controls Reward consummatory  1R Lateral Globus Pallidus106−21038425.07L Lateral Globus Pallidus−104024.63L Parahippocampal Gyrus34−180−1213.16R Caudate Body818612.73  2L Medial Frontal Gyrus.−4482286421.02  3R Red Nucleus4−22−8143214.40L Red Nucleus−4−16−49.87L Substania Nigra−8−16−128.77  4R Putamen260−644010.84 Reward anticipation  1L Lateral Globus Pallidus−12602073649.99R Caudate Head106046.31R Red Nucleus6−26−819.19L Red Nucleus−6−22−814.62L Caudate Body−1241811.84R Subthalamic Nucleus12−12−810.90L Mammillary Body0−12−1010.89R Mammillary Body4−12−810.89R Hypothalamus10−6−810.87  2R Inferior Frontal Gyrus475014−271212.80R Superior Temporal Gyrus385218−810.66  3R Insula133616655211.67  4L Medial Frontal Gyrus10−254442410.84  5L Anterior Lobe.Culmen.0−60−641610.58 Emotional processing  1L Medial Frontal Gyrus32−81246100018.60  2R Posterior Lobe.Declive34−52−1276820.80  3L Medial Frontal Gyrus90463268816.68  4L Inferior Frontal Gyrus−4218262416.42  5R Middle Temporal Gyrus3946−721452816.92  6R Fusiform Gyrus1924−80−1056016.04  7R Inferior Frontal Gyrus94283052017.43  8L Medial Frontal Gyrus10−260−247212.04L Medial Frontal Gyrus10−250−410.96  9L Posterior Lobe.Declive.−30−56−1445617.93  10R Cuneus1928−843249617.23  11R Anterior Cingulate32640045617.93Patients (mixed MDD and SZ) Reward consummatory  1L Lateral Globus Pallidus−1240245613.93L Parahippocampal Gyrus34−240−1013.69L Putamen−148−812.20  2L Anterior Cingulate10−454−2195218.72L Anterior Cingulate24−63829.12  3R Insula13384−4154414.48  4R Amydala22−2−10142416.94  5R Caudate Head680119216.25  6L Red Nucleus0−22−8114411.76  7L Inferior Frontal Gyrus9−54123048812.78 Reward anticipation  1R Putamen148−2316829.48  2L Putamen−1410−4253616.57  3R Inferior Frontal Gyrus954202652813.44  4L Superior Frontal Gyrus9−1493240010.66 Emotional processing  1R Declive34−52−12116821.69  2R Middle Temporal Gyrus3946−721481617.43  3R Inferior Frontal Gyrus94483077618.06  4L Declive−30−56−1468018.96  5R Cuneus1929−853257617.52  6L Caudate Body−18201449611.39  7L Middle Occipital Gyrus19−44−78243211.38  8L Superior Frontal Gyrus9−6522443211.89*p \<* 0.01, FDR corrected, cluster size \>400 mm^3^; *BA =* Brodmann areaFig. 2Significant ALE maps (FDR corrected, *p* \< 0.01, cluster size \>400 mm3) of within-group analysis in healthy control group (HC) and transdiagnostic patient group (mixed MDD and SZ) for reward consummatory, reward anticipation, and emotional processing

### Patients (mixed MDD and SZ) {#Sec10}

For reward consummatory (11 studies and 68 foci), ALE analysis found seven statistically significant activation clusters, including left GPe, right caudate head, left red nucleus, right insula, left anterior cingulate gyrus (ACC), IFG and amydala. Reward anticipation (14 studies and 63 foci) was related to the significant activation of putamen, superior frontal gyrus (SFG) and IFG. As to the emotional processing (7 studies and 83 foci), increased likelihood of activation was observed in several frontal gyrus, temporal gyrus, occipital gyrus, as well as caudate body (*p* \< 0.01, FDR corrected, cluster size \> 400 mm3, Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). The results of within-group analysis results in MDD or SZ separately showed the similarly distribution and activation pattern (details see Table [S1](#MOESM1){ref-type="media"} and Fig. [S1](#MOESM1){ref-type="media"}).

Between-group ALE analysis in a transdiagnostic approach across MDD and SZ {#Sec11}
--------------------------------------------------------------------------

### Consummatory anhedonia {#Sec12}

For consummatory anhedonia (29 studies and 151 foci), ALE analysis revealed five statistically significant clusters with decreased likelihood of activation in patients compared to controls (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}), including bilateral caudate head and body, bilateral GPe, left putamen, right red nucleus, left ventral lateral nucleus and pulvinar, as well as MTG (*p* \< 0.01,, FDR corrected, cluster size \> 400 mm^3^). No brain regions showed increased likelihood of activation in patients compared to controls.Fig. 3Significant ALE maps (FDR corrected, *p* \< 0.01, cluster size \>400 mm3) of between-group analysis in a transdiagnostic approach across MDD and SZ for three subdomains: (**a**) consummatory anhedonia (**b**) anticipatory anehdonia and (**c**) emotional processing. Red and blue areas depict regions with increased and decreased likelihood of activation in the healthy controls than that in patients, respectivelyTable 3ALE results in a transdiagnostic approach across MDD and SZClusterAnatomical RegionBAXYZVolume mm^3^Maximum ALE Value (10^−3^)Consummatory anhedonia Control \> patients  1L Caudate Head−68−2469621.54R Caudate Body12101214.07R Caudate Head66212.22R Lateral Globus Pallidus146−611.06R Caudate Body1016−810.26  2L Putamen−20812121618.35L Putamen−262410.70L Putamen−244−49.51L Lateral Globus Pallidus−18−489.25  3R Red Nucleus4−22−680018.22  4L Pulvinar−12−24460814.71L Ventral Lateral Nucleus−10−1269.73  5R Middle Temporal Gyrus3746−56249616.42Anticipatory anhedonia Control \> patients  1R Caudate Head812−4524821.63L Putamen−148−221.38L Caudate Head−414210.62  2R Hippocampus28−20−856013.83  3L Anterior Cingulate3204685609.84L Medial Frontal Gyrus10−452147.77  4L Middle Frontal Gyrus8−32145248811.88  5R Parahippocampal Gyrus1922−48−446410.95 Patients \> control  1R Middle Frontal Gyrus938263856013.87  2L Inferior Frontal Gyrus9−46123050413.98Emotional processing Control \> patients  1R Lateral Globus Pallidus144−4290417.11R Amygdala20−4−1215.81R Putamen2014−215.73  2R Anterior Lobe. Culmen6−38−4164017.06L Parahippocampal Gyrus30−6−38411.84  3R Inferior Frontal Gyrus472632−888817.17  4R Medial Dorsal Nucleus12−20683212.56R Ventral Lateral Nucleus14−161411.42  5L Medial Frontal Gyrus9−4402273612.87L Anterior Cingulate32−1032129.50  6L Superior Temporal Gyrus38−4614−1268815.57  7L Amygdala−18−4−1444816.22  8L Middle Temporal Gyrus22−56−28040015.16 Patients \> control  1L Middle Occipital Gyrus37−44−66−6116013.15L Fusiform Gyrus19−46−74−109.57*p \<* 0.01, FDR corrected, cluster size \>400 mm^3^; *BA* = Brodmann area

### Anticipatory anhedonia {#Sec13}

For anticipatory anhedonia (30 studies and 119 foci), prefrontal cortex and striatal areas showed significantly different activity (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Decreased likelihood of activation was observed in bilateral caudate head, left putamen, right hippocampus and parahippocampus, ACC, mPFC and MFG (*p* \< 0.01, FDR corrected, cluster size \> 400 mm^3^). Increased likelihood of activation was observed in the left IFG and MFG.

### Emotional processing {#Sec14}

For the emotional experience task (31 studies and 163 foci), decreased likelihood of activation was observed in a number of brain areas from the cortical-subcortical network (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}), including right GPe, right putamen, right medial dorsal nucleus and ventrolateral nucleus of thalamus, bilateral amygdala, left parahippocampal gyrus, right IFG, left mPFC, left ACC and STG/MTG (*p* \< 0.01, FDR corrected, cluster size \> 400 mm^3^). Increased likelihood of activation was observed in the left middle occipital gyrus and fusiform gyrus.

Between-group ALE analysis in MDD or SZ {#Sec15}
---------------------------------------

### MDD {#Sec16}

For consummatory anhedonia in MDD (21 studies and 107 foci), decreased likelihood of activation was observed in the left GPe, right caudate body, left putamen, right insula and left ACC (*p* \< 0.01, FDR corrected, cluster size \> 400 mm3; Table S2 and Fig. [4](#Fig4){ref-type="fig"}). No areas with increased likelihood activation were observed.Fig. 4Significant ALE maps (FDR corrected, *p* \< 0.01, cluster size \>400 mm3) of between-group analysis in MDD or SZ respectively for three subdomains: (**a**) consummatory anehdonia (**b**) anticipatory anhedonia and (**S**) emotional processing. Red areas depict the regions with significant different activation between MDD patients and healthy controls. Green areas depict regions with significant different activation between SZ patients and healthy controls. ALE clusters are projected on a standard anatomical template in axial orientation, referring to Talairach space

For anticipatory anhedonia in MDD (17 studies and 89 foci), decreased likelihood of activation was observed in bilateral caudate head and left MFG, and increased activation was observed in left IFG and right MFG.

For emotional processing in MDD (25 studies and 124 foci), decreased likelihood of activation was observed in right GPe and putamen, bilateral amygdala and anterior lobe, right IFG and left ACC, and increased activation was observed in middle occipital gyrus and fusiform gyrus.

### SZ {#Sec17}

For consummatory anhedonia in SZ (8 studies and 44 foci), decreased likelihood of activation was observed in left putamen and caudate head, pulvinar and right red nucleus (*p* \< 0.01, FDR corrected, cluster size \> 400 mm3; Table [S3](#MOESM1){ref-type="media"} and Fig. [4](#Fig4){ref-type="fig"}). No areas with increased likelihood of activation were observed.

For anticipatory anhedonia in SZ (13 studies and 30 foci) decreased likelihood of activation was observed in left putamen, ACC, and mPFC and right caudate head. No areas with increased likelihood of activation were observed.

For emotional processing in SZ (6 studies and 39 foci), decreased likelihood of activation was observed in the right ventral lateral nucleus. No areas with increased likelihood of activation were observed.

Discussion {#Sec18}
==========

This review used a transdiagnostic, meta-analytic approach (ALE) to explore the neuronal basis of anhedonia across three subdomains: consummatory anhedonia, anticipatory anhedonia and emotional processing. Results revealed that consummatory anhedonia was associated with decreased activation in ventral basal ganglia areas, ventral tegmental area (VTA) and various subcortical areas. Anticipatory anhedonia was related to dysfunctions within basal ganglia regions like caudate and putamen, as well as various subregions of prefrontal cortex, such as anterior cingulate, medial frontal gyrus and middle frontal gyrus. Emotional processing of positive-valence stimuli was related to more distributed dysfunction, involving more of basal ganglia (putamen and GPe), thalamus, limbic regions (amygdala and parahippocampal gyrus), prefrontal cortex (IFG, mPFC, ACC), STG and middle occipital gyrus. Meta-analyses of MDD and SZ respectively revealed similar impairments in brain regions and activation patterns in consummatory and anticipatory anhedonia in these two diseases, but differences in emotional processing.

The neural correlates of different reward processing component {#Sec19}
--------------------------------------------------------------

The within-group analysis results of healthy controls showed that the three reward processing components related with anhedonia were differentially recruited the subregions in the basal ganglia and forebrain. Specifically, the reward consummatory processing was mainly concentrated on a series of subcortical regions including GPe, ventral striatum, SN, as well as mPFC and extended orbitofrontal cortex, which is consistent with a number of animal and human studies (Der-Avakian and Markou [@CR25]). Recent researches suggests that the opioid and GABA-ergic systems may play important role in that hedonic responses (at least to primary sensory stimuli). On the other side, reward anticipatory processing was more involved in dorsal striatum and cortical areas except for the ventral striatum and medial profrontal areas,, such as inferior frontal gyrus and insula. Those results highlighted importance of frontostriatal circuitry in reward anticipatory/prediction processing (Barch and Dowd [@CR6]; Jarbo and Verstynen [@CR66]) and indicated that further investigation are needed on identifying the connectivites between subareas of frontal cortex and striatum for specific reward component. Unlike the neural correlates of reward consummatory and anticipation, the within-group analyses for emotional processing task revealed much more widely distributed cortical areas in healthy controls, but not many subcortical regions. Those results suggested that the activated brain areas in emotional experience task may be the synthesis of various cognitive and emotional response related with reward. Furthermore, both the transdiagnostic analysis with mixed patients group and the analysis with MDD or SZ group separately showed a similarly contributed but less activated pattern with that of healthy controls in each of the subdomains of anhedonia.

Transdiagnostic neural markers of anhedonia {#Sec20}
-------------------------------------------

In both MDD and SZ, anhedonia is considered to be a core clinical characteristic (Griffiths et al. [@CR53]; Treadway et al. [@CR123]; Wang et al. [@CR137]). Animal studies have demonstrated parallel substrates across different disorders associated with altered anhedonia-related processing (Barr and Phillips [@CR7]; Der-Avakian and Markou [@CR24]). Therefore, researchers suggested that common pathological mechanisms could underlie anhedonia-related processing, supporting a transdiagnostic approach to reveal these underlying cognitive and neurobiological mechanisms. In this review, we applied an ALE meta-analysis to MDD and SZ to provide an integrated framework of the neural bases of anhedonia.

Based on the results of this transdiagnostic meta-analysis, consummatory anhedonia is related to decreased activation in several subcortical regions, such as caudate head and body, putamen, red nucleus, GPe, and pulvinar. Animal studies have demonstrated involvement of the ventral striatum and ventral pallidum in the experience of pleasure and hedonic perception of rewards (Berridge and Kringelbach [@CR11]; Kelley et al. [@CR72]). Furthermore, patients with ventral pallidus damage have significantly reduced responses to rewards or pleasant stimuli (Miller et al. [@CR87]; Vijayaraghavan et al. [@CR130]). Consistent with previous findings, our meta-analysis further implicated the opioid and GABA-ergic systems in the nucleus accumbens shell and its projections to the ventral pallidum, in deficits of in-the-moment hedonic experience. Specifically, reduced caudate activation has been reported to be associated with blunted processing of incentive perception and reinforcement learning in both MDD and SZ (Dowd and Barch [@CR30]; Pizzagalli [@CR100]; Pizzagalli et al. [@CR102]). A more recent conceptualization of pulvinar function posited that this region plays an important role in emotional salience and awareness (Hamilton et al. [@CR59]; Pessoa and Adolphs [@CR98]) and has strong bidirectional connectivity with insula and dACC (Mufson and Mesulam [@CR91]). Given this role of the pulvinar, we propose that low-level pulvinar activation may blunt hedonic experience through insufficient attention and awareness of reward-related information. To summarize, ALE meta-analysis on consummatory anhedonia processing emphasized the critical role of ventral basal ganglia and medial prefrontal pathways in generating the in-the-moment hedonic value representation and experience.

For anticipatory anhedonia, ALE showed involvement of the caudate and putamen, as well as several prefrontal subregions, such as dACC (BA32), mPFC and MFG. Previous studies suggested that multiple prefrontal-striatal pathways and reciprocal connections within subregions of PFC play an important role in regulating behavioral response to rewards or pleasurable stimuli in the motivational/anticipatory stage (Der-Avakian and Markou [@CR25]; Salamone and Correa [@CR109]). For instance, disruption of glutamatergic signaling between the mPFC and nucleus accumbens resulted in avolition for rewards (Faure et al. [@CR41]). Moreover, striatal lesions or dopamine depletion in striatum or dACC impaired the computation of effort-related costs, which then lead to a deficit of effort-based decision-making as the expected rewards were discounted (Croxson et al. [@CR20]). Preclinical studies further stressed that dACC plays an important role in signaling the net value (benefits minus costs) during social interactions (Apps and Ramnani [@CR3]). In brief, during the anticipation stage for reward or pleasurable stimuli, abnormal activation in mPFC, dACC and MFG may lead to failure to anticipate forthcoming rewards, including updating/maintaining the value of pleasant stimuli, effort-value computation, decision-making to engage in goal-directed activity and monitoring incentive-based behavioral responses (Haber and Knutson [@CR56]; Pujara and Koenigs [@CR103]; Wallis and Kennerley [@CR132]). The results of our meta-analysis consistently indicated that a number of brain regions and pathways, involving many neurotransmitter systems, mediated different aspects of anhedonia-related deficits. Consequently, this preliminary neural framework supports the conceptualization of anhedonia as a symptom with multiple components. Rigorous experimental paradigms and careful designs should be carried out in future work to provide a more refined description of anhedonia and to separate the neural bases of each aspect of anhedonia-related processing.

Our ALE analysis for anticipatory anhedonia also revealed reduced activation of the hippocampus and parahippocampal gyrus, which could impair retrieval of previous autobiographical memories and their incorporation into working memory to represent the value of a reward and anticipate a pleasurable stimulus (Adcock et al. [@CR1]; Zhu et al. [@CR141]; Mazgaj et al. [@CR85]). However, we did not observe any significant group difference between patients and controls in orbitofrontal cortex (OFC), which is considered to be a key cortical region involved in anhedonia, in particular in the reward value presentation (Kringelbach [@CR78]; Pizzagalli [@CR100]). One possible explanation is that detection of OFC is challenging for functional MRI experiments using regular EPI sequences due to strong magnetic susceptibility variation near the air-filled sinuses and corresponding signal loss and distortion (Faro et al. [@CR40]; Osterbauer et al. [@CR96]). Future investigation of this unique structure will benefit from advances in imaging sequences or MRI hardware.

Given the complex neural pathways in the frontal-striatal-thalamic circuitry, it is necessary to further divide each subcortical structure (e.g., striatum) into subregions to investigate the function of different cortical-subcortical connections. For instance, the striatum can be divided into three functional subregions (i.e., limbic, associative and sensorimotor) based on afferent inputs from the frontal cortex (Haber [@CR55]; Haber et al. [@CR57]; Iversen [@CR65]; van den Bos et al. [@CR129]). Consummatory anhedonia is mainly associated with limbic/ventral striatum, including anterior and ventral caudate and putamen (Corral-Frias et al. [@CR19]; Pizzagalli et al. [@CR102]), whereas anticipatory anhedonia is associated with both limbic/ventral striatum and associative striatum, including the dorsal caudate and anterior part of the dorsal putamen (Delgado [@CR23]; Dichter et al. [@CR27]; Mucci et al. [@CR90]). The results of our meta-analysis provide new evidence that dysfunction in distinct frontal-striatal pathways contributes to the different components of anhedonia-related processing. Based on this preliminary neural framework, further studies are needed to identify the functional and structural connections underlying these components of anhedonia-related processing.

ALE analysis of the emotional experience task revealed more widely distributed differences between patients and controls. In addition to blunted activation in basal ganglia and thalamus, a number of regions in limbic areas, prefrontal cortex, temporal cortex, and cerebellum also showed decreased activation in patients, whereas the visual association cortices showed increased activation. Given that the emotional experience task required no response and may include various cognitive and affective components, it is unclear whether those different activations reflect only the neural bases of anhedonia. Recent resting-state fMRI showed that different neural circuits were engaged in the emotional task-general and emotion task-specific processing (Cole et al. [@CR18]), which would be differently activated by the emotional experience task between controls and patients with affective symptoms. Moreover, functional connectivity analysis demonstrated distinct circuits associated with severity of general affective symptoms (i.e., depression) and anhedonia (Gabbay et al. [@CR47]). Indeed, a set of brain regions, including the anterior and posterior cingulate, mPFC, basal ganglia and visual areas, were activated during passive viewing of positive-valence stimuli, but the ventral striatum and mPFC were the key regions correlated with self-reported anhedonia severity (Epstein et al. [@CR38]; Harvey et al. [@CR60]). Therefore, more elaborate experimental designs will be required to explore the underlying neural bases of general mood-related processing and specific emotional experiences (e.g., hedonia).

Disease-specific findings: MDD and SZ {#Sec21}
-------------------------------------

To further explore anhedonia-related neural mechanisms and identify potential disease-specific or task-specific confounders, ALE analysis was compared between MDD and SZ patients across the three anhedonia subdomains. In general, anhedonia-related impairment was consistent between MDD and SZ patients across the consummatory and anticipatory stages. Those findings suggest that the neural substrates involved in accurate appraisal of positive stimuli and generation of reward responses, but not the substrates underlying hedonic emotion arousal, are likely to be the core brain areas associated with anhedonia. Furthermore, these data provide a partial explanation for the discordance between self-reported trait pleasure and momentary pleasure in previous behavioral studies: MDD and SZ patients reported normative affective ratings in response to evocative laboratory stimuli, but low positive affect and pleasurable experiences on evaluation of inventories (Osuch et al. [@CR97]; Pizzagalli [@CR99]; Strauss [@CR118]; Treadway and Zald [@CR121]). From a cognitive processing pespective, laboratory-based assessment of consummatory anhedonia may reflect the capacity for hedonic experience, while the patient self-reports in clinical interviews and inventories might reflect both the hedonic experience deficit and the inability to accurately represent incentive experiences. Based on this interpretation, the theoretical definition of anhedonia for research and targeted treatment may need to be modified.

In contrast to the consummatory and anticipatory anhedonia domains, which were similar across MDD and SZ, emotional experience tasks showed striking differences. In MDD patients, decreased activation was much more widely distributed across brain regions, including basal ganglia, amygdala, frontal gyrus and cerebellum; SZ patients only showed decreased activation in thalamus. As previously noted, the emotional experience task requires no response and may reflect other cognitive and affective components. Our results support that the emotional experience task induced both affective/mood-related and anhedonia-specific responses. It is worth noting that only blunted activation in part of ventral basal ganglia was correlated with anhedonia in MDD patients viewing positive valence pictures (Epstein et al. [@CR38]; Mitterschiffthaler et al. [@CR88]; Osuch et al. [@CR97]), which was highly consistent with the correlations between dysfunctional BOLD signals and anhedonia in a consummatory anhedonia task (Gradin et al. [@CR52]; Pizzagalli et al. [@CR102]). Overall, it appears that an emotional experience task, such as passively viewing pictures or words, may not be a pure measure of anhedonia (i.e., consummatory anhedonia) and may capture the affective responses related with general mood, which may influence results in populations with prominent depressive symptoms.

Limitations {#Sec22}
-----------

Potential limitations of this study should be noted. First of all, ALE technique does have its own limitations. Unlike the meta-analyses in which the complete activation maps are included, the data used in ALE were based solely on reported peak activation coordinates. Thereby ALE could not take into account those studies without any significant clusters reported, which may resulting in a systematic overestimation bias of the results. Besides, the present ALE software cannot conduct the correlation analysis or deal with covariates, thus the only way to consider the covariates was run follow-up analyses, e.g., only on experiments investigating only female subjects or unmedicated patients when considering the gender or medication effect. An additional limitation of the ALE is that it may be unable to assess subtle methodological differences in individual studies such as the thresholding used in the original studies, relative strength of activations/differences between groups and differences in preprocessing steps (Radua and Mataix-Cols [@CR104]). Nevertheless, previous studies suggested that no individual study could significantly bias the results of ALE meta-analyses after including the sample size and number of reported foci into ALE algorithm, changing from fixed-effects to random-effects inference, and revising for multiple comparison correction (Eickhoff et al. [@CR34]; Turkeltaub et al. [@CR126]; Eickhoff et al. [@CR35]; Kollndorfer et al. [@CR77]). In the present study, the robustness of results was further supported by the reasonably coherent findings in within-group ALE analysis of various reward processing components and between-group analyses of subdomains of anhedonia, which were also consistent with previous neurobioglogical studies on animals.

Secondly, given that the patients in 31/35 MDD studies and 22/25 SZ studies were treated in their lifetime by antidepressant or antipsychotics, the drug effects on the brain activated pattern in reward-related processing are potential confounding factors which need to be addressed (Clarke et al. [@CR17]; Boccia et al. [@CR13]). Most antidepressant treatments act on the serotonergic or noradrenergic circuits, but not directly enhance Dopamine (DA) neurotransmission, which plays a significant role in motivation and reward processing (Berridge [@CR10]; Treadway and Zald [@CR121]). However, recent literature showed that the antidepressant mechanism such as increasing serotonin (5-HT) originating from midbrain raphe nuclei (RN), could sequentially decrease the dopamine inhibition and increased ventral striatal activity to reward in humans and animals (Dremencov et al. [@CR32]; Dunlop and Nemeroff [@CR33]; Ossewaarde et al. [@CR95]; El Yacoubi et al. [@CR36]). As for the antipsychotic treatment that directly impacts the DA neurotransmission, evidence showed that the first generation (typical) and second generation (atypical) antipsychotic medications had different effects on the neural correlates of reward/motivation tasks (Juckel et al. [@CR69], [@CR70]; Kirsch et al. [@CR74]; Schlagenhauf et al. [@CR110]). For instance, Kirsch et al. found that patients with typical antipsychotics showed reduced ventral striatal activation, while atypically treated patients showed significantly stronger activation of the right ventral striatum. Those results were further supported by a controlled, longitudinal study (Nielsen et al. [@CR93]) . The different impact of typical and atypical antipsychotics on reinforcement learning of reward processing were also supported by both behavioral evidences (Beninger et al. [@CR8]; Keri et al. [@CR73]) and neuroimaging data (Insel et al. [@CR64]). Further clinical and basic studies are needed to reveal the underlying mechanism of those effects.

Conclusion and future directions {#Sec23}
--------------------------------

In summary, our ALE meta-analysis supported characterization of anhedonia by alterations in reward processing, which contain multiple complicated components and rely on many brain regions within frontal-striatal circuitry. Specifically, consummatory anhedonia was associated with decreased activation in ventral striatum and pallidum, while anticipatory anhedonia was more associated with more substrates in frontal-striatal networks except the ventral striatum, which included the dorsal anterior cingulate, middle frontal gyrus and medial frontal gyrus. However, the emotional experience task (passive viewing of positive pictures or words) revealed mixed findings, including dysfunction in both the anhedonia-related and affective/mood processing regions. Therefore, the transdiagnostic approach holds promise for providing both overall and specific neurobiological frameworks of anhedonia.

Although our meta-analysis presents novel, meaningful evidence regarding the neurobiology of anhedonia, it only distinguished the neural substrates of motivation to pursue rewards and hedonic response to rewards. Future work is needed to dissect the different neurobiological pathways that are related to the various reward-processing subcomponents, such as perceiving pleasure, encoding reward value, calculating costs and benefits, learning from prior reinforcement, making decisions and execute the action to pursue a reward. It is important to note that anhedonia also plays an important role in several other psychiatric and neurological disorders, such as Parkinson's disease (Loas et al. [@CR83]), post-traumatic stress disorder (Frewen et al. [@CR45]) and drug addiction (Balodis and Potenza [@CR5]; Hatzigiakoumis et al. [@CR61]), albeit in heterogeneous ways. Therefore, combining more categories of disorders and using a greater sample size in future studies should further elucidate the neural foundations of anhedonia.
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